Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer

Summary

This clinical trial studies widefield fluorescence and reflectance imaging, fluorescence spectroscopy, and tissue samples in regularly examining (monitoring) participants at risk for developing oral cancer. All tissue and cells are made of tiny particles. Some of these particles give off small amounts of light. This light is called fluorescence. Fluorescent imaging use instruments that shine different wavelengths (colors) of light in the mouth taking fluorescence pictures through a portable head light or by taking fluorescent and reflectance pictures through a dental microscope using a digital camera. Fluorescent spectroscopy uses a small probe placed gently against the lining of the mouth and the tissue is exposed to small amounts of fluorescent light that is then collected with a special camera and a computer to be analyzed. Checking mouth tissue samples under a microscope may also help detect abnormal cells. Diagnostic procedures, such as fluorescence and reflectance imaging, fluorescence spectroscopy imaging, and tissue samples, may help doctors detect pre-cancer or early cancer when it may be easier to treat.

Conditions

• Erythroplakia
• Fanconi Anemia
• Lichen Planus
• Oral Cavity and Lip Precancerous Condition
• Oral Cavity Leukoplakia
• Oral Neoplasm
• Premalignant Lesion
• Tobacco Use Disorder

Interventions

OTHER

Cytology Specimen Collection Procedure

Undergo oral tissue collection

PROCEDURE

Diagnostic Microscopy

Mouth tissue examined microscopically for cytologic features

PROCEDURE

Diagnostic Procedure

Undergo standard white light headlamp oral examination

PROCEDURE

Fluorescence Imaging

Undergo widefield fluorescent and reflectance imaging

PROCEDURE

Fluorescence Spectroscopy

Undergo point fluorescent spectroscopy

Sponsors & Collaborators

• National Cancer Institute (NCI)

  collaborator NIH

• M.D. Anderson Cancer Center

  lead OTHER

Principal Investigators

• Ann M Gillenwater · M.D. Anderson Cancer Center

Study Design

Allocation

NA

Purpose

DIAGNOSTIC

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2007-08-27

Primary Completion

2027-04-30

Completion

2027-04-30

Countries

• United States

Study Locations